Expertise in
11
conditions
Expertise in
11
conditions
Nguyen Surgical Associates PC
540 W Plumb Ln Ste 200, 
Reno, NV 

Overview

Alan Ikeda is a Hematologist and an Oncologist in Reno, Nevada. Dr. Ikeda is highly rated in 11 conditions, according to our data. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Ewing Sarcoma, Hepatoblastoma, Osteosarcoma, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 11 peer reviewed articles and participating in 54 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in CA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Silversummit Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 3 Less Insurance Carriers -

Locations

Nguyen Surgical Associates PC
540 W Plumb Ln Ste 200, Reno, NV 89509
Other Locations
Arthur M. Blank Hospital
2220 N Druid Hills Rd NE, Atlanta, GA 30329

Additional Areas of Focus

Dr. Ikeda has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


54 Clinical Trials

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Neuroblastoma Biology Studies
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Renal Tumors Classification, Biology, and Banking Study
Key Adverse Events After Childhood Cancer
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
View 49 Less Clinical Trials
Similar Doctors
Expertise in
41
conditions
Hematology | Oncology
Expertise in
41
conditions
Hematology | Oncology

Cancer Care Specialists

5423 Reno Corporate Drive, 
Reno, NV 
 (347.8 miles away)
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Sowjanya Reganti is a Hematologist and an Oncologist in Reno, Nevada. Dr. Reganti is highly rated in 41 conditions, according to our data. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Familial Colorectal Cancer, and Familial Pancreatic Cancer. Dr. Reganti is currently accepting new patients.

Expertise in
59
conditions
Hematology | Oncology
Expertise in
59
conditions
Hematology | Oncology

Cancer Care Specialists

5423 Reno Corporate Drive, 
Reno, NV 
 (347.8 miles away)
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Suresh Reddy is a Hematologist and an Oncologist in Reno, Nevada. Dr. Reddy is highly rated in 59 conditions, according to our data. His top areas of expertise are Paget Disease of the Breast, Angiosarcoma, Inflammatory Breast Cancer, Neuroendocrine Tumor, and Bone Marrow Aspiration. Dr. Reddy is currently accepting new patients.

Expertise in
70
conditions
Hematology | Oncology
Expertise in
70
conditions
Hematology | Oncology

Cancer Care Specialists

5423 Reno Corporate Drive, 
Reno, NV 
 (347.8 miles away)
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Santhosh Ambika is a Hematologist and an Oncologist in Reno, Nevada. Dr. Ambika is highly rated in 70 conditions, according to our data. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Follicular Lymphoma, Hodgkin Lymphoma, and Bone Marrow Aspiration. Dr. Ambika is currently accepting new patients.

Frequently Asked Questions about Dr. Alan Ikeda

How do I make an appointment with Dr. Alan Ikeda?

You can book an appointment with Dr. Alan Ikeda by calling their office at 775-657-8981. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Alan Ikeda a top-rated expert for Acute Lymphoblastic Leukemia (ALL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Alan Ikeda is classified as an Advanced expert for Acute Lymphoblastic Leukemia (ALL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Alan Ikeda specialize in?

While Dr. Alan Ikeda is a Hematology, they have specific expertise in Acute Lymphoblastic Leukemia (ALL), Ewing Sarcoma, and Hepatoblastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Alan Ikeda participate in research or clinical trials?

Yes. Dr. Alan Ikeda has published 11 articles and abstracts on conditions like Acute Lymphoblastic Leukemia (ALL). You can view a list of Dr. Alan Ikeda's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Alan Ikeda accept my insurance?

Dr. Alan Ikeda accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 775-657-8981 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ikeda's expertise for a condition
ConditionClose
      View All 11 Advanced Conditions
      View All 31 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile